Source: Annual Congress 2005 - COPD - treatment I
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Munoz, I. Alfageme, N. Reyes, J. Perez, M. Merino, F. Gonzalez, F. Saez, P. Martin (Madrid, Seville, Spain). Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV). Eur Respir J 2005; 26: Suppl. 49, 1914

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021 Year: 2022 Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Influenza and pneumococcal vaccination in patients with COPD Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001 Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016